Search This Site

Implementing a New Patient Registry and Care Coordinator to Address Palivizumab Administration for Eligible Infants and Toddlers

Presenters Name: 
Jana Mirafuente
Primary Research Mentor: 
Martha Hellems
Secondary Research Mentor: 
9:30 - 9:45
Time of Presentation: 
2019 - 9:30am to 9:45am
South Meeting Room
Presentation Type: 
Presentations Academic Category: 
Grant Program Recipient: 
USOAR Program

RSV is a common respiratory virus that causes wheezing and coughing in young children, but for infants born prematurely, especially those born with chronic lung and heart conditions, RSV can be deadly. Palivizumab, also known as Synagis, is a preventive treatment administered monthly during the RSV season that has decreased infant hospitalizations due to RSV. However, the cost to manufacture palivizumab and the complexity of eligibility criteria for the treatment has recently obscured the treatment’s accessibility and overall success of treatment. To address this problem during the 2018-2019 RSV season, UVA’s Division of General Pediatrics has implemented a new patient registry and care coordinator to more efficiently keep track of patients as they receive palivizumab. We are comparing the timelines of palivizumab administration from this 2018-2019 RSV season to the 2017-2018 season’s performance to determine whether the implemented strategies are effective in increasing the rate of timely and complete administration during the RSV season. Because this current RSV season is not yet through, there is no clear conclusion that can be made regarding improved efficiency. Analyses will be completed within the next month.